The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Identifying subtle differences in tumor cells can help treat endometrial cancer better

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found that the two test results differ because there are underlying subtle differences in the cells that make up an endometrial cancerous tumor. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Jemperli + Zejula improved PFS in advanced or recurrent endometrial cancer in RUBY Part 2 phase III trial

In a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy, in adult patients with primary advanced or recurrent endometrial cancer, the trial met its primary endpoint of progression-free survival.
Clinical Roundup

Phase III trial of Jemperli + chemo meets endpoint of OS in primary advanced or recurrent endometrial cancer

Part 1 of the phase III RUBY trial of Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel) followed by dostarlimab as a single agent, compared to placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer produced positive primary results from a planned analysis.
Clinical Roundup

DUO-E phase III trial: Imfinzi + Lynparza reduces risk of progression/death vs. chemo in advanced/recurrent endometrial cancer

Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy alone in the overall trial population of patients with newly diagnosed advanced or recurrent endometrial cancer. 
Clinical Roundup

Keytruda + chemo improved PFS as first-line therapy for advanced or recurrent endometrial carcinoma, regardless of MMR status

In a phase III NRG‑GY018 trial investigating Keytruda (pembrolizumab) in combination with standard of care chemotherapy (carboplatin and paclitaxel) for the first-line treatment of patients with stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient or mismatch repair deficient, the Keytruda regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients, regardless of mismatch repair status. 
Clinical Roundup

Keytruda + chemo met primary endpoint as first-line therapy for advanced or recurrent endometrial carcinoma

The phase III NRG-GY018 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival for the treatment of patients with stage 3-4 or recurrent endometrial carcinoma regardless of mismatch repair status. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account